| Niacin | cardiovascular prevention, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.34 [0.01 8.57] | p=1.00 | 0 | 97 | 1 | UCSF SCOR, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.34 [0.01 8.57] | p=1.00 | 0 | 97 | 1 | UCSF SCOR, | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | 1.05 [0.50 2.21] | p=1.00 | 0 | 220 | 1 | VA drugs, | | MACE | no data | | Non fatal MI | no data | | All cause death | 1.03 [0.51 2.08] | p=1.00 | 0 | 220 | 1 | VA drugs, | | non cardiovascular death | 0.93 [0.17 5.19] | p=1.00 | 0 | 220 | 1 | VA drugs, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| VA drugs, 1968 | niacin | | | | UCSF SCOR, 1990 | Niacin 0–7.5 g colestipol 15–20 g | Conventional therapy | patients with heterozygous familial hypercholesterolemia |
| |
| Niacin | | vs placebo | Coronary event by 17% suggested Non fatal MI by 27% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Venous thromboembolism | no data | | cardiovascular events | 0.22 [0.04 1.05] | p=1.00 | 0 | 100 | 1 | FATS, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.83 [0.72 0.96] | p=0.04 | 0 | 4463 | 2 | Carlson (Stockholm), CDP niacin, | | Coronary death and non fatal MI | no data | | Coronary death | 0.89 [0.75 1.05] | p=1.00 | 0 | 4463 | 2 | Carlson (Stockholm), CDP niacin, | | cardiac death | no data | | MACE | no data | | Non fatal MI | 0.73 [0.60 0.89] | p=0.04 | 0 | 4463 | 2 | Carlson (Stockholm), CDP niacin, | | All cause death | 0.92 [0.80 1.07] | p=1.00 | 0 | 4463 | 2 | Carlson (Stockholm), CDP niacin, | | non cardiovascular death | 1.15 [0.76 1.72] | p=1.00 | 0 | 3908 | 1 | CDP niacin, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.85 [0.44 1.65] | p=1.00 | 0 | 4463 | 2 | Carlson (Stockholm), CDP niacin, | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CLAS, 1987 | colestipol + niacin | placebo | nonsmoking men aged 40 to 59 years with previous coronary bypass surgery | | Carlson (Stockholm), 1977 | clofibrate, 1 g twice daily, and nicotinic acid 1 g three times daily | control | survivors of a myocardial infarction below 70 years of age | | CDP niacin, 1975 | niacin 3 mg/d | placebo | Hommes, de 30 à 64 ans | | FATS, 1990 | niacin (1 g four times a day) and colestipol (10 g three times a day) | placebo (or colestipol if the low-density lipoprotein [LDL] cholesterol level was elevated) | men no more than 62 years of age with apolipoprotein B levels greater than or equal to 125 mg per deciliter, documented coronary artery disease, and a family history of vascular disease |
| |
| Niacin | | vs placebo (on top statin) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.96 [0.90 1.03] | p=1.00 | 0 | 29414 | 4 | AIM-HIGH, HPS 2-Thrive, ARBITER 2, HATS, | | Cardiovascular death | 1.09 [0.95 1.24] | p=1.00 | 0 | 26000 | 3 | HPS 2-Thrive, ARBITER 2, HATS, | | stroke (fatal and non fatal) | 1.02 [0.90 1.15] | p=1.00 | 0 | 29330 | 4 | AIM-HIGH, HPS 2-Thrive, ARBITER 2, HATS, | | Coronary event | 0.97 [0.88 1.07] | p=1.00 | 0 | 29325 | 4 | AIM-HIGH, HPS 2-Thrive, ARBITER 2, HATS, | | All cause death | 1.09 [0.98 1.21] | p=1.00 | 0 | 25833 | 2 | HPS 2-Thrive, HATS, |
| Trial | Studied treatment | Control | Patients |
|---|
| AIM-HIGH, 2011 | high-dose, extended-release niacin in gradually increasing doses up to 2000 mg daily (+ simvastatin) | placebo | patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesterol | | HPS 2-Thrive, | 2 g of extended-release niacin and 40 mg of laropiprant | placebo | patients with vascular disease | | Oxford Niaspan Study, 2009 | niacin 2g daily (added to statin therapy) | placebo (statins alone) | patients with low HDL-C (<40 mg/dl) and either a type 2 diabetes with coronary heart disease or a carotid/peripheral atherosclerosis | | ARBITER 2, 2009 | long-acting niacin target dose of 1 g/day (added to statin therapy) | placebo | patients with known coronary artery disease and well controlled on statin therapy | | HATS, 2001 | simvastatin plus niacin | placebo | patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels |
| |
| Niacin | | vs ezetimibe | cardiovascular events by 2849% suggested Coronary event by 79% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 29.49 [15.39 56.51] | p=0.04 | 0 | 363 | 1 | ARBITER 6-HALTS (niacin vs ezetimibe), | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | 0.21 [0.04 0.98] | p=0.04 | 0 | 363 | 1 | ARBITER 6-HALTS (niacin vs ezetimibe), | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| ARBITER 6-HALTS (niacin vs ezetimibe), 2009 | extended-release niacin 1 g/d, titrated to max tolerable dose up to 2 g/d (HDL-focused strategy) | ezetimibe 10 mg/d (LDL-focused strategy) | patients with known coronary or vascular disease or coronary risk equivalents |
| |
| Niacin | | vs simvastatin+ezetimibe | cardiovascular events by 2153% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 22.53 [5.52 91.90] | p=0.04 | 0 | 948 | 1 | Guyton, | | Cardiovascular death | no data | | stroke (fatal and non fatal) | 0.13 [0.01 3.30] | p=1.00 | 0 | 948 | 1 | Guyton, | | Coronary event | 0.40 [0.03 6.46] | p=1.00 | 0 | 948 | 1 | Guyton, | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Guyton, 2008 | Niacin 2 g ezetimibe 10 mg simvastatin 20 mg | Ezetimibe 10 mg simvastatin 20 mg | patients with type IIa or IIb hyperlipidemia |
| |
